Santen Inc. Announces Appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical
Emeryville, CA, April 01, 2020 – Santen, Inc., a U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, today announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical. As of April 1, he is also appointed as CEO of Santen Inc. and he will lead the company’s North America business and report to Shigeo Taniuchi, President and CEO of Santen Pharmaceutical.
“Tatsuya’s expertise and valuable contributions have had a transformative impact on Santen and our employees,” said Shigeo Taniuchi. “I am confident that his leadership will further strengthen our business in North America and allow us to make great strides toward our mission of protecting vision for patients around the world.”
Since joining Santen in 2017, Kaihara has served as Chief Strategy Officer and Deputy Chief Executive and Financial Officer of Santen Inc. He also held the position of Chief Investment Officer for Santen Ventures, Inc., the company’s North American corporate ventures capital fund which invests in research and development projects and partners focused on innovations in ophthalmology.
“Santen has a promising pipeline in North America as we continue to work together to help advance ophthalmic innovations to address the unmet needs of patients,” said Tatsuya Kaihara. “I look forward to the next phase of growth for the company and working with a team that has demonstrated unparalleled commitment to helping those affected by vision loss.”
Santen Forward-looking Statements
Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen websites www.SantenUSA.com (United States) and www.santen.com (global).